249 related articles for article (PubMed ID: 32215450)
21. Tuberculosis: clinical trials and new drug regimens.
Kwon YS; Jeong BH; Koh WJ
Curr Opin Pulm Med; 2014 May; 20(3):280-6. PubMed ID: 24614239
[TBL] [Abstract][Full Text] [Related]
22. Elucidating the role of clofazimine for the treatment of tuberculosis.
O'Donnell MR; Padayatchi N; Metcalfe JZ
Int J Tuberc Lung Dis; 2016 Dec; 20(12):52-57. PubMed ID: 28240574
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.
Borisov SE; Dheda K; Enwerem M; Romero Leyet R; D'Ambrosio L; Centis R; Sotgiu G; Tiberi S; Alffenaar JW; Maryandyshev A; Belilovski E; Ganatra S; Skrahina A; Akkerman O; Aleksa A; Amale R; Artsukevich J; Bruchfeld J; Caminero JA; Carpena Martinez I; Codecasa L; Dalcolmo M; Denholm J; Douglas P; Duarte R; Esmail A; Fadul M; Filippov A; Davies Forsman L; Gaga M; Garcia-Fuertes JA; García-García JM; Gualano G; Jonsson J; Kunst H; Lau JS; Lazaro Mastrapa B; Teran Troya JL; Manga S; Manika K; González Montaner P; Mullerpattan J; Oelofse S; Ortelli M; Palmero DJ; Palmieri F; Papalia A; Papavasileiou A; Payen MC; Pontali E; Robalo Cordeiro C; Saderi L; Sadutshang TD; Sanukevich T; Solodovnikova V; Spanevello A; Topgyal S; Toscanini F; Tramontana AR; Udwadia ZF; Viggiani P; White V; Zumla A; Migliori GB
Eur Respir J; 2017 May; 49(5):. PubMed ID: 28529205
[TBL] [Abstract][Full Text] [Related]
24. Interactions of linezolid and second-line anti-tuberculosis agents against multidrug-resistant Mycobacterium tuberculosis in vitro and in vivo.
Zhao W; Zheng M; Wang B; Mu X; Li P; Fu L; Liu S; Guo Z
Int J Infect Dis; 2016 Nov; 52():23-28. PubMed ID: 27613365
[TBL] [Abstract][Full Text] [Related]
25. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
Bada FO; Blok N; Okpokoro E; Dutt S; Akolo C; Dakum P; Abimiku A
PLoS One; 2020; 15(12):e0241065. PubMed ID: 33259492
[TBL] [Abstract][Full Text] [Related]
26. Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.
Xia H; van den Hof S; Cobelens F; Zhou Y; Zhao B; Wang S; Zhao Y
BMC Infect Dis; 2020 Jan; 20(1):19. PubMed ID: 31910878
[TBL] [Abstract][Full Text] [Related]
27. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
Ding Y; Zhu H; Fu L; Zhang W; Wang B; Guo S; Chen X; Wang N; Liu H; Lu Y
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0065822. PubMed ID: 35924925
[TBL] [Abstract][Full Text] [Related]
28. Linezolid for drug-resistant pulmonary tuberculosis.
Singh B; Cocker D; Ryan H; Sloan DJ
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012836. PubMed ID: 30893466
[TBL] [Abstract][Full Text] [Related]
29. Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis.
Grace AG; Mittal A; Jain S; Tripathy JP; Satyanarayana S; Tharyan P; Kirubakaran R
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012918. PubMed ID: 31828771
[TBL] [Abstract][Full Text] [Related]
30. A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way.
Deshpande D; Srivastava S; Nuermberger E; Pasipanodya JG; Swaminathan S; Gumbo T
Clin Infect Dis; 2016 Nov; 63(suppl 3):S95-S101. PubMed ID: 27742640
[TBL] [Abstract][Full Text] [Related]
31. New drugs and perspectives for new anti-tuberculosis regimens.
Tiberi S; Muñoz-Torrico M; Duarte R; Dalcolmo M; D'Ambrosio L; Migliori GB
Pulmonology; 2018; 24(2):86-98. PubMed ID: 29487031
[TBL] [Abstract][Full Text] [Related]
32. New and Repurposed Drugs for the Treatment of Active Tuberculosis: An Update for Clinicians.
Aguilar Diaz JM; Abulfathi AA; Te Brake LH; van Ingen J; Kuipers S; Magis-Escurra C; Raaijmakers J; Svensson EM; Boeree MJ
Respiration; 2023; 102(2):83-100. PubMed ID: 36516792
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
Zhang SJ; Yang Y; Sun WW; Zhang ZS; Xiao HP; Li YP; Zhang ZM; Fan L
BMC Infect Dis; 2022 Aug; 22(1):715. PubMed ID: 36038829
[TBL] [Abstract][Full Text] [Related]
34. Therapy of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis.
Seaworth BJ; Griffith DE
Microbiol Spectr; 2017 Mar; 5(2):. PubMed ID: 28361737
[TBL] [Abstract][Full Text] [Related]
35. Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations.
Kendall EA; Malhotra S; Cook-Scalise S; Denkinger CM; Dowdy DW
BMC Infect Dis; 2019 Sep; 19(1):794. PubMed ID: 31500572
[TBL] [Abstract][Full Text] [Related]
36. MDR Tuberculosis Treatment.
Espinosa-Pereiro J; Sánchez-Montalvá A; Aznar ML; Espiau M
Medicina (Kaunas); 2022 Jan; 58(2):. PubMed ID: 35208510
[TBL] [Abstract][Full Text] [Related]
37. Tuberculosis clinical trial update and the current anti-tuberculosis drug portfolio.
Palomino JC; Martin A
Curr Med Chem; 2013; 20(30):3785-96. PubMed ID: 23862617
[TBL] [Abstract][Full Text] [Related]
38. Editorial: Updates from the World Health Organization (WHO) on Global Treatment Recommendations for Drug-Susceptible and Multidrug-Resistant Tuberculosis.
Parums DV
Med Sci Monit; 2021 Aug; 27():e934292. PubMed ID: 34366429
[TBL] [Abstract][Full Text] [Related]
39. Incidence rate and time to serious adverse events among rifampicin resistant tuberculosis patients in Georgia treated with new and repurposed anti-tuberculosis drugs, 2016-2018.
Buziashvili M; Davtyan H; Sereda Y; Denisiuk O; Gozalov O; Lomtadze N; Hovhannesyan A
Monaldi Arch Chest Dis; 2021 Jan; 91(1):. PubMed ID: 33470083
[TBL] [Abstract][Full Text] [Related]
40. Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings.
Sotgiu G; Tiberi S; Centis R; D'Ambrosio L; Fuentes Z; Zumla A; Migliori GB
Int J Infect Dis; 2017 Mar; 56():190-193. PubMed ID: 27816662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]